D. Fruman
Molecular Biology · 2000–2023
A researcher in the Science corpus: 4 papers; trusts 7 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 146 citations into it
- Genetics — 37 citations into it
Whom D. Fruman trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- B. Vanhaesebroeck
- C. V. Dang
- K. Okkenhaug
- B. Manning
- Christian C. Dibble
- C. Lord
- J. Engelman
- Heather L. Wieman
- S. Farkona
- Nicholas McGranahan
Who trusts D. Fruman overall
Papers from D. Fruman's perspective
Ordered by how strongly the researchers D. Fruman trusts endorse each paper. Same corpus, a different order for every researcher.
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex (Science)
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancer (Nature Reviews. Cancer)
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer (Nature Medicine)
- TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling (Nature Cell Biology)
- High Frequency of Mutations of the PIK3CA Gene in Human Cancers (Science)
- mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. (Cancer Research)
- AKT/PKB signaling: navigating downstream. (Cell)
- SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth (Cell Metabolism)
- Activation of a metabolic gene regulatory network downstream of mTOR complex 1. (Molecules and Cells)
- The phosphoinositide 3-kinase pathway. (Science)
Their papers
- The PI3K pathway in human disease (2017) — 2,352 citations
- PI3K and Cancer: Lessons, Challenges and Opportunities (2014) — 1,640 citations
- PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023) — 1,782 citations
- Impaired Kit- but Not FcεRI-initiated Mast Cell Activation in the Absence of Phosphoinositide 3-Kinase p85α Gene Products* (2000) — 84 citations